Abstract
One hundred and sixty-two breast carcinomas treated by adjuvant chemotherapy were investigated in immunohistochemistry for expression of p53 and two wild-type p53-regulated induced proteins, mdm2 and p21/waf1. p21 and mdm2 were expression stongly correlated with Ki67 but not with survival. The p53+/p21+, p53+/p21- and p53+/mdm2- phenotypes were associated with the worst prognosis. The p53+/p21+/ mdm2+ tumors were associated with a better outcome than the other phenotypes, they may be tumors expressing wild-type p53 and p21, and a form of mdm2 that might lead to the stabilization of p53. It is suggested that p21/mdm2 expression should be investigated in all cases of p53 positive breast cancer.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / mortality
-
Breast Neoplasms / pathology*
-
Breast Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Cyclin-Dependent Kinase Inhibitor p21
-
Cyclins / analysis*
-
Enzyme Inhibitors / analysis
-
Female
-
Humans
-
Immunohistochemistry
-
Ki-67 Antigen / analysis
-
Lymph Nodes / pathology
-
Neoplasm Proteins / analysis
-
Nuclear Proteins*
-
Predictive Value of Tests
-
Prognosis
-
Proto-Oncogene Proteins / analysis*
-
Proto-Oncogene Proteins c-mdm2
-
Receptors, Estrogen / analysis
-
Receptors, Progesterone / analysis
-
Retrospective Studies
-
Survival Rate
-
Tumor Suppressor Protein p53 / analysis
Substances
-
Antibiotics, Antineoplastic
-
CDKN1A protein, human
-
Cyclin-Dependent Kinase Inhibitor p21
-
Cyclins
-
Enzyme Inhibitors
-
Ki-67 Antigen
-
Neoplasm Proteins
-
Nuclear Proteins
-
Proto-Oncogene Proteins
-
Receptors, Estrogen
-
Receptors, Progesterone
-
Tumor Suppressor Protein p53
-
MDM2 protein, human
-
Proto-Oncogene Proteins c-mdm2